HPV Associated Disorders Market Report 2025

This HPV Associated Disorders market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The HPV associated disorders market size has grown strongly in recent years. It will grow from $20.73 billion in 2024 to $22.34 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising prevalence of HPV-associated disorders, increasing awareness about HPV and its associated disorders, advancements in diagnostic technologies, government initiatives for HPV vaccination programs, growing demand for early screening and vaccination.

The HPV associated disorders market size is expected to see strong growth in the next few years. It will grow to $29.66 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to approval of new HPV vaccines, increasing initiatives by government and private organizations for early screening and vaccination, rising incidence of cervical cancer, growing demand for non-invasive diagnostic tests, integration of HPV testing in routine healthcare. Major trends in the forecast period include development of next-generation HPV vaccines, adoption of point-of-care HPV testing, shift towards molecular techniques in HPV detection, personalized approaches in HPV management, integration of HPV testing in women's health services.

The HPV-associated disorders market is expected to witness growth due to an increased prevalence of HPV-related cases. These disorders encompass a range from benign verrucae vulgates and condylomas acuminata to malignancies such as cervical, vulva, anus, and penis cancers, as well as anogenital warts, recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. The global burden is significant, particularly among women. For instance, a report from cancer. net in January 2022 estimated that 14,100 women in the United States would be diagnosed with invasive cervical cancer, and globally, 604,127 women were diagnosed with cervical cancer in 2020. Additionally, in 2023, an estimated 4,310 deaths from cervical cancer occurred in the United States, emphasizing the need for advancements in the HPV-associated disorders market.

A driving factor in the HPV-associated disorders market is the decline in contraceptive use. Contraceptives play a crucial role in preventing unplanned pregnancies, and a reduction in their market share can lead to an increase in the number of individuals at risk of HPV infection, a known risk factor for disorders like cervical cancer. A report in December 2022 revealed an 8% reduction in the overall value of the public-sector contraceptive market across 83 Low and Middle-Income Countries (LMICs). This decline, from $285 million in 2020 to $263 million in 2021, underscores the impact on the HPV-associated disorders market.

Targeted therapies are an emerging trend gaining traction in the treatment of HPV-associated disorders. Major players in the field are developing and adopting these therapies to address conditions such as cervical cancer, oropharyngeal cancer, and others. Targeted therapies include medications that focus on specific proteins, such as vascular endothelial growth factor (VEGF) and tissue factor (TF) proteins, in cancer cells. For example, in September 2023, INOVIO Pharmaceuticals, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational product, INO-3107, aimed at treating Recurrent Respiratory Papillomatosis (RRP). This designation is crucial as it accelerates the development and review process for therapies targeting serious conditions, especially when preliminary evidence indicates significant improvement over existing treatments. INO-3107 has demonstrated the ability to induce durable immune responses against HPV types 6 and 11, activating both CD4+ and CD8+ T cells, which are essential for targeting infected cells.

Major companies in the HPV-associated disorders market are introducing HPV vaccines to combat diseases related to the virus. HPV vaccines are vital for public health as they help reduce the incidence of HPV-related diseases and support cervical cancer screening and prevention initiatives. For example, in January 2023, the Serum Institute of India launched CERVAVAC, the first indigenously developed human papillomavirus (HPV) vaccine designed to prevent cervical cancer in women. This vaccine employs L1 virus-like particles (VLPs) to stimulate an immune response without causing infection. This approach effectively primes the immune system to recognize and combat HPV upon future exposure.

In May 2022, GlaxoSmithKline plc, a UK-based biopharmaceutical company, acquired Affinivax, Inc. for $2. 1 billion. This strategic acquisition enhances GSK plc's vaccine R&D pipeline by providing access to Affinivax's innovative vaccine technology platform, MAPS (Multiple Antigen Presenting System). Affinivax, Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing next-generation vaccine technology platforms.

Major companies operating in the HPV associated disorders market include AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Eli Lilly and Company, Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Ipsen S. A., Bayer AG, Eisai Co. Ltd., Genentech Inc., Medtronic plc, Novo Nordisk A/S, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Lupin Limited.

North America was the largest region in the HPV associated disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hpv associated disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hpv associated disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The disorders associated with the human papillomavirus pertain to a virus capable of triggering abnormal tissue growth, such as warts and various cell irregularities. Transmission of these disorders primarily occurs through sexual intercourse or other forms of skin-to-skin contact. Vaccination, medications, and other diagnostic measures can aid in safeguarding against HPV types that lead to HPV-related cancer.

The primary manifestations of HPV-associated disorders include cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, genital warts, and other indications. The cervical intraepithelial indication of HPV-associated disorder is employed for the prevention and treatment of cervical intraepithelial neoplasia. Cervical intraepithelial neoplasia (CIN) denotes abnormal alterations in the cells lining the cervix. The management of HPV-associated disorders involves preventive and therapeutic measures, which are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

The HPV associated disorders market research report is one of a series of new reports that provides HPV associated disorders market statistics, including HPV associated disorders industry global market size, regional shares, competitors with a HPV associated disorders market share, detailed HPV associated disorders market segments, market trends and opportunities, and any further data you may need to thrive in the HPV associated disorders industry. This HPV associated disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human papillomavirus-associated disorders market includes revenues earned by entities by plantar warts and flat warts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.